Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance.
Blog Post
Enormous changes are underway in HIV prevention and across global health. It’s our work to vigilantly track impacts on research, development and delivery and to call out inequity, greed, misinformation, and misguided assumptions. Here are three questions advocates are asking now along with resources to support this work.
Blog Post
This week major shifts in development finance make headlines as do the real-time consequences of the US cuts to foreign aid and withdrawing from the WHO. AVAC’s new issue of PxWire amplifies issues of access, equity, and accountability with an update on biomedical prevention research and rollout.
Blog Post
The global burden of STIs is staggering with more than one million treatable STIs being acquired daily, and new threats like antibiotic-resistant gonorrhea and rising syphilis cases demanding urgent action. Yet funding, research, and political attention lag far behind the need.
showing 1-10 of 1141
Enormous changes are underway in HIV prevention and across global health. It’s our work to vigilantly track impacts on research, development and delivery and to call out inequity, greed, misinformation, and misguided assumptions. Here are three questions advocates are asking now along with resources to support this work.
This week major shifts in development finance make headlines as do the real-time consequences of the US cuts to foreign aid and withdrawing from the WHO. AVAC’s new issue of PxWire amplifies issues of access, equity, and accountability with an update on biomedical prevention research and rollout.
The global burden of STIs is staggering with more than one million treatable STIs being acquired daily, and new threats like antibiotic-resistant gonorrhea and rising syphilis cases demanding urgent action. Yet funding, research, and political attention lag far behind the need.
This issue provides a range of maps to help orient the field on critical HIV prevention activities: the status of delivering injectable cabotegravir (CAB for PrEP); funders and countries on track for early introduction of injectable lenacapavir (LEN for PrEP); and where new Phase 3 efficacy trials testing MK-8527 as a monthly pill for PrEP are taking place.
The US government shutdown escalated this week as the Administration laid off thousands of workers before chaotically retracting many of these notices. The UK-based Children’s Investment Fund Foundation (CIFF) abruptly cut all funding to US-based NGOs, and world leaders urged a streamlined global health system amid funding cuts.
As the US government is in its second week of being shut down, the ripple effects across global health shows the interconnectedness of the public health infrastructure in the US and globally and uncertainty about the future of foreign aid. Amid this turmoil, the World Health Organization has prequalified injectable lenacapavir for PrEP in record time, using a new, expedited process.
This roundup from AVAC highlights key developments across the field of HIV prevention from accelerating access to lenacapavir, to advancing inclusion of pregnant and lactating people, and trans and gender-diverse communities in research.
This is not the time to scrub tran and gender diverse people inclusion from HIV trial designs and protocols. Now is the moment to use everything at our disposal to set in motion an era of HIV research that meaningfully responds to this community’s needs.
The US government shutdown that began at midnight on October 1 has stalled key public health operations just as the Supreme Court issued a ruling in AVAC v. Department of State that allowed $4 billion dollars in foreign aid to expire, eroding both health and human services and constitutional checks and balances. Meanwhile, Jeanne Marrazzo was officially fired as Director of NIAID, underscoring how politically motivated attacks on science are dismantling the infrastructure that has underpinned decades of progress in HIV prevention and research.
Prevention Option:
Late today in AVAC v Department of State and Global Health Council v Trump, the Supreme Court of the United States granted the US Presidential Administration’s request to stay an injunction that would require the Administration to obligate $4 billion of foreign assistance funds before they expire on September 30, as required by law. The Court’s ruling temporarily grants the Administration’s request to pause a lower court order that the government spend the funds. With just four days until September 30, those funds, which otherwise would have saved lives and advanced global health and national security, will remain unspent.
Prevention Option:
showing 1-10 of 1141
Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.
A comprehensive round-up of HIV prevention media coverage and scientific publications.
Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.
PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.
Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.
A collection of official statements from AVAC.
Media clippings featuring AVAC, its staff and close partners in the news media.